CYTO
Altamira Therapeutics Ltd. [CYTO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CYTO Stock Summary
Top 10 Correlated Stocks
CYTO
In the News
CYTO Financial details
Company Rating
Sell
Market Cap
2.89M
Income
-336.32K
Revenue
1.59M
Book val./share
-0.43
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
10 Apr 2024
P/E
-0.09
Forward P/E
-
PEG
0.02
P/S
12.26
P/B
-0.29
P/C
144
P/FCF
-0.35
Quick Ratio
0.06
Current Ratio
0.14
Debt / Equity
-1.9
LT Debt / Equity
-0.67
-
-
EPS (TTM)
-11.4
EPS next Y
-
EPS next Q
-
EPS this Y
10.93%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-36.81%
Revenue last 5Y
-24.74%
Revenue Q/Q
-91.07%
EPS Q/Q
-85.77%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-60%
Inst Own
62.56%
Inst Trans
1.5%
ROA
-421%
ROE
-1209%
ROC
3.97%
Gross Margin
-372%
Oper. Margin
-8551%
Profit Margin
-8680%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.61-29.0
52W High
-95.03%
52W Low
+44%
RSI
37
Rel Volume
0.02
Avg Volume
1.21M
Volume
25.31K
Perf Week
-20.88%
Perf Month
-23.4%
Perf Quarter
-57.04%
Perf Half Y
-61.86%
-
-
-
-
Beta
2.536
-
-
Volatility
0.13%, 0.25%
Prev Close
-4%
Price
1.44
Change
-1.37%
CYTO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 31.85 | -0.39 | 0.58 | 0.1 | 0.34 | |
| Net income per share | -289.2 | -45.6 | -27.27 | -26.26 | -29.13 | |
| Operating cash flow per share | -332.87 | -57.71 | -16.11 | -20.64 | -9.53 | |
| Free cash flow per share | -380.44 | -78.46 | -23.81 | -25.67 | -11.89 | |
| Cash per share | 135.67 | 9.52 | 37.44 | 1.49 | 0.02 | |
| Book value per share | 91.81 | 41.5 | 55.77 | 19.18 | -9.13 | |
| Tangible book value per share | 2.88 | -5.02 | 25.45 | -2.43 | -13.41 | |
| Share holders equity per share | 91.81 | 41.5 | 55.77 | 19.18 | -9.13 | |
| Interest debt per share | 63.03 | 0.2 | 2.19 | 1.16 | 7.95 | |
| Market cap | 142.64M | 91.3M | 277.82M | 439.34M | 81.65M | |
| Enterprise value | 138.68M | 89.91M | 267.09M | 438.94M | 87.97M | |
| P/E ratio | -12.41 | -13.77 | -33.88 | -25.26 | -3.08 | |
| Price to sales ratio | 112.67 | -1.63K | 1.59K | 6.88K | 267.17 | |
| POCF ratio | -10.78 | -10.88 | -57.36 | -32.13 | -9.4 | |
| PFCF ratio | -9.43 | -8 | -38.81 | -25.85 | -7.54 | |
| P/B Ratio | 39.08 | 15.12 | 16.57 | 34.58 | -9.82 | |
| PTB ratio | 39.08 | 15.12 | 16.57 | 34.58 | -9.82 | |
| EV to sales | 109.54 | -1.61K | 1.53K | 6.87K | 287.84 | |
| Enterprise value over EBITDA | -12.66 | -12.42 | -50.56 | -25.79 | -3.38 | |
| EV to operating cash flow | -10.48 | -10.71 | -55.14 | -32.1 | -10.13 | |
| EV to free cash flow | -9.17 | -7.88 | -37.31 | -25.82 | -8.13 | |
| Earnings yield | -0.08 | -0.07 | -0.03 | -0.04 | -0.32 | |
| Free cash flow yield | -0.11 | -0.13 | -0.03 | -0.04 | -0.13 | |
| Debt to equity | 0.39 | 0 | 0.03 | 0.05 | -0.76 | |
| Debt to assets | 0.15 | 0 | 0.03 | 0.03 | 1 | |
| Net debt to EBITDA | 0.36 | 0.19 | 2.03 | 0.02 | -0.24 | |
| Current ratio | 1.33 | 1.04 | 3.83 | 0.77 | 0.14 | |
| Interest coverage | -10.24 | -253.57 | -39.09 | -90.14 | -28.66 | |
| Income quality | 1.15 | 1.27 | 0.59 | 0.79 | 0.33 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.37 | -70.25 | 14.87 | 76.64 | 11.52 | |
| Research and developement to revenue | 5.28 | -59.38 | 16.41 | 139.93 | 64.39 | |
| Intangibles to total assets | 0.36 | 0.73 | 0.44 | 0.76 | 0.62 | |
| Capex to operating cash flow | 0.14 | 0.36 | 0.48 | 0.24 | 0.25 | |
| Capex to revenue | -1.49 | 53.9 | -13.27 | -52.06 | -7.01 | |
| Capex to depreciation | -26.01 | -97.93 | -115.55 | -43.56 | -18.02 | |
| Stock based compensation to revenue | 0.02 | -4.05 | 2.11 | 18.88 | 1.12 | |
| Graham number | 772.93 | 206.33 | 184.98 | 106.45 | 77.35 | |
| ROIC | -2.19 | -1.17 | -0.3 | -1.24 | 17.16 | |
| Return on tangible assets | -1.81 | -2.7 | -0.7 | -3.84 | -11.01 | |
| Graham Net | -15.94 | -3.41K | -571.31 | -6.08 | -15.4 | |
| Working capital | 1.5M | 95.8K | 8.59M | -1.1M | -11.11M | |
| Tangible asset value | 114.41K | -729.48K | 7.65M | -1.61M | -12.21M | |
| Net current asset value | -162.35K | -816.15K | 7.59M | -2.37M | -12.85M | |
| Invested capital | 0.39 | 0 | 0.03 | 0.05 | -0.76 | |
| Average receivables | 280.83K | 327.84K | 208.08K | 510.22K | 851.05K | |
| Average payables | 1.52M | 1.39M | 850.35K | 2.15M | 4.16M | |
| Average inventory | -79.94K | -494.29M | -673.33M | -178.67M | 425.43K | |
| Days sales outstanding | 92.37 | -2.19K | 169.16 | 5.37K | 910.68 | |
| Days payables outstanding | 0 | 0 | 0 | 577.4 | 1.21K | |
| Days of inventory on hand | 0 | 0 | 0 | 136.71 | 2.94 | |
| Receivables turnover | 3.95 | -0.17 | 2.16 | 0.07 | 0.4 | |
| Payables turnover | 0 | 0 | 0 | 0.63 | 0.3 | |
| Inventory turnover | 0 | 0 | 0 | 2.67 | 124 | |
| ROE | -3.15 | -1.1 | -0.49 | -1.37 | 3.19 | |
| Capex per share | -47.57 | -20.75 | -7.7 | -5.02 | -2.35 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.67 | 0 | 0 | 0 | 0.03 | |
| Net income per share | -9.98 | 0 | 0 | 0 | -1.42 | |
| Operating cash flow per share | -7.64 | 0 | 0 | 0 | -2.02 | |
| Free cash flow per share | -9.74 | 0 | 0 | 0 | -2.02 | |
| Cash per share | 0.48 | 0 | 0 | 0 | 0.01 | |
| Book value per share | 9.9 | 0 | 0 | 0 | -0.43 | |
| Tangible book value per share | -10.55 | 0 | 0 | 0 | -1.36 | |
| Share holders equity per share | 9.9 | 0 | 0 | 0 | -0.43 | |
| Interest debt per share | 7.25 | 0 | 0 | 0 | 0.96 | |
| Market cap | 144.28M | 0 | 0 | 0 | 48.15M | |
| Enterprise value | 149.13M | -15.4K | 6.32M | -49.57K | 51.57M | |
| P/E ratio | -4.66 | 0 | 0 | 0 | -2.03 | |
| Price to sales ratio | 111.43 | 0 | 0 | 0 | 416.41 | |
| POCF ratio | -24.37 | 0 | 0 | 0 | -5.68 | |
| PFCF ratio | -19.12 | 0 | 0 | 0 | -5.68 | |
| P/B Ratio | 18.8 | 0 | 0 | 0 | -26.39 | |
| PTB ratio | 18.8 | 0 | 0 | 0 | -26.39 | |
| EV to sales | 115.17 | 0 | 0 | 0 | 445.96 | |
| Enterprise value over EBITDA | -18.34 | 0 | 0 | 0 | -10.14 | |
| EV to operating cash flow | -25.19 | 0 | 0 | 0 | -6.08 | |
| EV to free cash flow | -19.77 | 0 | 0 | 0 | -6.08 | |
| Earnings yield | -0.05 | 0 | 0 | 0 | -0.12 | |
| Free cash flow yield | -0.05 | 0 | 0 | 0 | -0.18 | |
| Debt to equity | 0.68 | 0 | -0.76 | -0.51 | -1.9 | |
| Debt to assets | 0.28 | 0 | 1 | 0.15 | 0.56 | |
| Net debt to EBITDA | -0.6 | 0 | 0 | 0 | -0.67 | |
| Current ratio | 0.2 | 0.14 | 0.14 | 0.32 | 0.32 | |
| Interest coverage | -20.54 | 0 | 0 | 0 | -8.81 | |
| Income quality | 0.77 | 0 | 0 | 0 | 1.43 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 2.91 | 0 | 0 | 0 | 21.44 | |
| Intangibles to total assets | 0.86 | 0.62 | 0.62 | 0.63 | 0.63 | |
| Capex to operating cash flow | 0.27 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -1.25 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -25.8 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.15 | 0 | 0 | 0 | -31.77 | |
| Graham number | 47.17 | 0 | 0 | 0 | 3.72 | |
| ROIC | -0.61 | 0 | 0 | 0 | -2.52 | |
| Return on tangible assets | -2.94 | 0 | 0 | 0 | -2.57 | |
| Graham Net | -12.76 | 0 | 0 | 0 | -1.73 | |
| Working capital | -7.86M | -11.11M | -11.11M | -3.64M | -3.64M | |
| Tangible asset value | -8.18M | -12.21M | -12.21M | -5.72M | -5.72M | |
| Net current asset value | -8.88M | -12.85M | -12.85M | -6.3M | -6.3M | |
| Invested capital | 0.68 | 0 | -0.76 | -0.51 | -1.9 | |
| Average receivables | 0 | 316.36K | 384.52K | 397.16K | 409.93K | |
| Average payables | 0 | 3.97M | 4.77M | 3.37M | 1.96M | |
| Average inventory | 0 | 79.01K | 11.64K | 141.07K | 270.5K | |
| Days sales outstanding | 43.53 | 0 | 0 | 0 | 613.32 | |
| Days payables outstanding | 214.94 | 0 | 0 | 0 | 593.11 | |
| Days of inventory on hand | 9.94 | 0 | 0 | 0 | 81.68 | |
| Receivables turnover | 2.07 | 0 | 0 | 0 | 0.15 | |
| Payables turnover | 0.42 | 0 | 0 | 0 | 0.15 | |
| Inventory turnover | 9.05 | 0 | 0 | 0 | 1.1 | |
| ROE | -1.01 | 0 | 0 | 0 | 3.26 | |
| Capex per share | -2.1 | 0 | 0 | 0 | 0 |
CYTO Frequently Asked Questions
What is Altamira Therapeutics Ltd. stock symbol ?
Altamira Therapeutics Ltd. is a BM stock and trading under the symbol CYTO
What is Altamira Therapeutics Ltd. stock quote today ?
Altamira Therapeutics Ltd. stock price is $1.44 today.
Is Altamira Therapeutics Ltd. stock public?
Yes, Altamira Therapeutics Ltd. is a publicly traded company.
Company Profile
- Volume Average 1.21M
- Market Capitalization 2.89M
- Employee 16
- CEO Dr. Covadonga Paneda
- Headquarters Hamilton,BM
- IPO Date 2014-08-06
-
Website
https://altamiratherapeutics.com 
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
